Associate Professor, Medicine, UCLA School of Medicine
Hematology
Dr. John M. Timmerman, MD
|
|
Give Review
Doctor John M. Timmerman, MD practices Hematology. He studied medicine at Boston University School of Medicine. Boston University School of Medicine is ranked 30/52 in Research/PrimaryCare. He received 1 awards: "Super Doctor". Doctor John M. Timmerman, MD is also published. He has 47 publications published. The lastest publication: "Melanoma vaccines: prim and proper presentation.' John M. Timmerman, MD is registered with Medicare and accepts Medicare payments.
Publications
- Suppression of Fcγ-Receptor-Mediated Antibody Effector Function during Persistent Viral Infection.
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma.
- Antibody-cytokine fusion proteins for treatment of Cancer: engineering cytokines for improved efficacy and safety.
- Active Idiotypic Vaccination Versus Control Immunotherapy for Follicular Lymphoma.
- Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: ...
- High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular Lymphoma tumors from peripheral T cells.
- A Phase I Dose-Finding Trial of Recombinant Interleukin-21 and Rituximab in Relapsed and Refractory Low Grade B-cell Lymphoproliferative Disorders.
- Combination of Cyclophosphamide, Rituximab, and Intratumoral CpG Oligodeoxynucleotide Successfully Eradicates Established B cell Lymphoma.
- Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated Breast cancer patients.
- Programmed death ligand 1 (PD-L1) is expressed by non-Hodgkin Lymphomas and inhibits the activity of tumor-associated T cells.
- Targeted deLivery of interferon-alpha via fusion to anti-CD20 results in potent antitumor activity against B-cell lymphoma.
- Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin Lymphoma.
- Recombinant anti-CD20 antibody fragments for small-animal PET imaging of B-cell Lymphomas.
- Intratumoral but not systemic deLivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma.
- Carrier protein conjugate vaccines: the "missing link" to improved antibody and CTL responses?
- Sulfhydryl-based tumor antigen-carrier protein conjugates stimulate superior antitumor immunity against B cell Lymphomas.
- Dendritic cells loaded with apoptotic antibody-coated tumor cells provide protective immunity against B-cell Lymphoma in vivo.
- Vaccine therapies for non-Hodgkin's Lymphomas.
- Current status of therapeutic vaccines for non-Hodgkin's Lymphoma.
- Therapeutic idiotype vaccines for non-Hodgkin's Lymphoma.
- Extending the utility of gene profiling data by bridging microarray platforms.
- Antitumor immunity after vaccination with B Lymphoma cells overexpressing a triad of costimulatory molecules.
- Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell Lymphoma.
- Vaccine therapies for non-Hodgkin's Lymphoma.
- Idiotype-pulsed dendritic cell vaccination for B-cell Lymphoma: clinical and immune responses in 35 patients.
- ImmunoPET imaging of B-cell Lymphoma using 124I-anti-CD20 scFv dimers (diabodies).
- Recombinant, tumour-derived idiotype vaccination for indolent B cell non-Hodgkin''s Lymphomas: a focus on FavId.
- Enhanced immune stimulation by a therapeutic Lymphoma tumor antigen vaccine produced in insect cells involves mannose receptor targeting to antigen presenting cells.
- Maleimide conjugation markedly enhances the immunogenicity of both human and murine idiotype-KLH vaccines.
- Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin Lymphoma.
- Interleukin-21: biology and application to Cancer therapy.
- Immunotherapy for Lymphomas.
- Determinant spreading and tumor responses after peptide-based Cancer immunotherapy.
- BLyS and BLyS receptor expression in non-Hodgkin''s Lymphoma.
- Linkage of foreign carrier protein to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic Cell vaccine.
- Idiotype-encoding recombinant adenoviruses provide protective immunity against murine B-cell Lymphomas.
- In vivo antitumor effect of CD40L-transduced tumor cells as a vaccine for B-cell Lymphoma.
- A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell Lymphoma (DLBCL) and correlative analyses of patient-specific factors.
- Generation of CD8+ T cell-mediated immunity against idiotype-negative Lymphoma escapees.
- Clinical outcome of Lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype.
- Prolonged Disease-free survival and overall survival with CVP alternating with fludarabine in advanced follicular lymphoma.
- The history of the development of vaccines for the treatment of Lymphoma.
- Dendritic cell vaccines for Cancer immunotherapy.
- Melanoma vaccines: prim and proper presentation.
- Immunotherapy of Non-Hodgkin's Lymphomas.
- Malignant germ Cell tumors in men infected with the human immunodeficiency virus: natural history and results of therapy.
Schools
Boston Univ Sch Of Med
Procedures Preformed
- HPC Transplantation (Stem Cell Transplant)
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anemia
- Breast Cancer
- Chronic Myeloid Leukemia (CML)
- View All
Doctors Specialties
- Medical Oncology
- Oncology
- Hematology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Blue Card PPO
- CaliforniaCare HMO
- Advantage Preferred DirectAccess Plus PPO
- Blue Cross Blue Shield of California PPO
- Pathway X Direct Access PPO
- Pathway X Tiered Direct Access
- Select Plus HMO
- Select PPO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- First Health (Coventry Health Care) PPO
- Blue & Gold HMO
- Covered California - Bronze PPO
- Employer Group HMO
- Health Net PPO
- Individual and Family PPO
- Kaiser PHCS Network PPO
- MultiPlan PPO
- PHCS Network PPO
- Heritage Signature
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- PacifiCare HMO
Awards
- Super Doctor
Education
-
Stanford University -
UCSF -
Boston University School of Medicine
Hospital
-
Ronald Reagan UCLA Medical Center -
Santa Monica-UCLA Medical Center and Orthopaedic Hospital
Drug Facts
| NPI NUMBER | 1891715090 | |
| NPPES Provider LastName | TIMMERMAN | |
| NPPES Provider FirstName | JOHN | |
| NPPES Provider ZIPCode | 900953075 | |
| NPPES Provider State | CA | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 44.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1891715090 |
| Last Name Of The Provider | TIMMERMAN |
| First Name Of The Provider | JOHN |
| View All |
Similar Doctors
|
|
Dr. Kathryn A. Henick, MD |
|
|
Dr. Doris V. Quon, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Doris V. Quon, MD |